

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

**【Cover】**

<b>【Document Submitted】</b>	Extraordinary Report
<b>【Submitted to】</b>	Director, Kanto Local Finance Bureau
<b>【Date of Submission】</b>	June 18, 2021
<b>【Company Name】</b>	Ono Yakuhin Kogyo Kabushiki-Kaisha
<b>【Company Name (in English)】</b>	ONO PHARMACEUTICAL CO., LTD.
<b>【Position and Name of Representative】</b>	Gyo Sagara, President, Representative Director, and Chief Executive Officer
<b>【Location of Head Office】</b>	1-5, Doshomachi 2-chome, Chuo-ku, Osaka, Japan (The above is the location of the registered head office. The actual head office operations are located at 8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, Japan.)
<b>【Phone No.】</b>	Not applicable
<b>【Contact for Communications】</b>	Not applicable
<b>【Nearest Contact】</b>	8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka, Japan
<b>【Phone No.】</b>	+81-(0)6-6263-5670
<b>【Contact for Communications】</b>	Kazuhiro Nagahama, Senior Director, Finance & Accounting
<b>【Place Where Available for Public Inspection】</b>	Tokyo Stock Exchange, Inc. (2-1 Nihombashi Kabutocho, Chuo-ku, Tokyo, Japan)

## 1 【Reason for Filing】

As the following proposals were resolved at the 73rd Ordinary General Shareholders' Meeting of Ono Pharmaceutical Co., Ltd. (the "Company") held on June 17, 2021, the Company hereby files this Extraordinary Report pursuant to the provisions of Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and the provisions of Article 19, Paragraph 2, Item 9-2 of the Cabinet Office Ordinance on the Disclosure of Corporate Affairs, etc.

## 2 【Description of Report】

### (1) Date of the Ordinary General Shareholders' Meeting

June 17, 2021

### (2) Details of Proposals Resolved

#### Proposal 1 Appropriation of Surplus

##### Year-End Dividend

##### ① Type of dividend property

Cash

##### ② Allocation of dividend property to shareholders and total amount of such allocation

¥27.50 per share of common stock Total dividend amount: ¥13,728,173,058

##### ③ Effective date of the distribution of the dividend

June 18, 2021

#### Proposal 2 Election of Eight (8) Members of the Board of Directors

Eight (8) Members of the Board of Directors, namely, Gyo Sagara, Toshihiro Tsujinaka, Toichi Takino, Isao Ono, Kiyooki Idemitsu, Masao Nomura, Akiko Okuno and Shusaku Nagae were elected.

#### Proposal 3 Election of One (1) Audit & Supervisory Board Member

Audit & Supervisory Board Member Hironobu Tanisaka was elected to fill in for Shinji Fujiyoshi, who resigned as Audit & Supervisory Board Member at the close of the General Shareholders' Meeting.

#### Proposal 4 Determination of Specific Details of Stock-Based Remuneration-Type Stock Options for Members of the Board of Directors

Details of stock acquisition rights were determined based on the Act Partially Amending the Companies Act (Act No. 70 of 2019), which came into force on March 1, 2021, and other relevant regulations, in order to maintain the Company's current system of stock-based remuneration-type stock options (the allotment of stock acquisition rights to Members of the Board of Directors).

### (3) The number of voting rights either approving, disapproving or abstaining on proposals resolved; requirements for the approval of the resolutions and their results

Proposal	For (Number of voting rights)	Against (Number of voting rights)	Abstentions (Number of abstentions)	Requirements for approval	Results Approval ratio (%)
Proposal 1 Appropriation of Surplus	4,347,462	36,901	731	(Note 1)	Approved 99.127

Proposal	For (Number of voting rights)	Against (Number of voting rights)	Abstentions (Number of abstentions)	Requirements for approval	Results Approval ratio (%)
Proposal 2 Election of Eight (8) Members of the Board of Directors					
Gyo Sagara	4,265,596	118,195	1,416	(Note 2)	Approved 97.258
Toshihiro Tsujinaka	4,339,539	44,934	739		Approved 98.944
Toichi Takino	4,339,600	44,873	739		Approved 98.945
Isao Ono	4,312,175	72,298	739		Approved 98.320
Kiyooki Idemitsu	4,339,550	44,923	739		Approved 98.944
Masao Nomura	4,365,991	18,483	739		Approved 99.547
Akiko Okuno	4,366,222	18,252	739		Approved 99.552
Shusaku Nagae	4,375,003	9,471	739		Approved 99.753
Proposal 3 Election of One (1) Audit & Supervisory Board Member Hironobu Tanisaka	4,252,361	131,976	771	(Note 2)	Approved 96.959
Proposal 4 Determination of Specific Details of Stock-Based Remuneration-Type Stock Options for Members of the Board of Directors	4,310,804	73,639	771	(Note 1)	Approved 98.289

- Notes) 1. Proposal 1 and Proposal 4 require approval by a majority of voting rights of the shareholders in attendance eligible for exercising voting rights.
2. Proposal 2 and Proposal 3 require the attendance of shareholders holding one-third or more of voting rights owned by shareholders eligible for exercising voting rights and approval by a majority of said voting rights.

(4) The reason why a portion of the voting rights held by the shareholders in attendance at the Ordinary General Shareholders' Meeting was not counted

Resolutions of all the proposals have been legitimately reached in accordance with the Companies Act, as the requirements for approval have been met based on the number of confirmed votes of approval or disapproval by counting the voting rights exercised up to the day before this General Shareholders' Meeting and those of shareholders in attendance. Therefore, voting rights of the shareholders in attendance which are not confirmed as to whether they are approving, disapproving, or abstaining are not included in the count.